Galenica Aktie 36067446 / CH0360674466
Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen |
07.08.2025 06:45:06
|
Galenica demonstrates pleasing growth and improves EBIT guidance
Galenica AG / Key word(s): Half Year Results
Galenica recorded pleasing growth in a positive market environment in the first half of 2025. Both the “Products & Care” segment (+4.6%) and the “Logistics & IT” segment (+5.5%) contributed to the increase in sales of 5.0% to CHF 1,995.4 million. As a result, Galenica Group sales grew slightly stronger than the pharmaceutical market (+4.8%2) and the consumer healthcare market (+0.6%3). Strong sales growth in prescription drugsFollowing an increase of 4.7% by the end of April 2025, Galenica Group sales increased further in May and June 2025. Growth in the first half of the year was driven by strong demand for prescription drugs, including GLP-1-based4 weight loss products, as well as drugs associated with the heavy flu season early in the year. The good result was achieved despite one less day of sales compared to the same period in the previous year. Reported EBIT increased by 6.2% to CHF 108.8 million, while adjusted EBIT1 increased by 10.9% to CHF 109.9 million. In the first half of 2025, EBIT was supported by the pleasing sales growth as well as by positive one-off effects in the amount of CHF 5.4 million. Without these effects, adjusted EBIT1 would have increased by 5.4%. The reason for this is that fines in two competition proceedings were significantly lower than originally expected, positively impacting the “Logistics & IT” segment. Improved EBIT guidance for the second half of the yearGalenica confirms its 2025 outlook for consolidated net sales with growth of between 3% and 5% and the dividend at least at the same level as the previous year. Due to the strong growth in the first half of the year and positive one-time effects of CHF 5.4 million, Galenica now expects an EBIT1 increase of between 7% and 9%. Prior to this, growth of between 4% and 6% had been expected. In early July 2025, Galenica announced the acquisition of the diagnostics service provider Labor Team. As the closing date of the transaction has not yet been determined, the Labor Team Group is not yet included in the 2025 guidance. Key figures of the Galenica Group in the first half of 2025
1) Excluding the effects of IFRS 16 and IAS 19 (details of the adjusted key figures in the half year report 2025) 2) IQVIA, Pharmaceutical Market Switzerland, YTD June 2025. 3) IQVIA, Consumer Health Market Switzerland, YTD June 2025. 4) GLP-1 stands for glucagon-like peptide 1, a hormone produced in the intestine and which plays an important role in regulating blood sugar levels.
Detailed information in the half year report 2025:
Upcoming dates
For further information, please contact:
Welcome to the Galenica network! Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information about Galenica can be found at www.galenica.com. End of Inside Information |
Language: | English |
Company: | Galenica AG |
Untermattweg 8 | |
3027 Bern | |
Switzerland | |
Phone: | +41 058 852 81 11 |
E-mail: | info@galenica.com |
Internet: | https://www.galenica.com |
ISIN: | CH0360674466 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 2180242 |
End of Announcement | EQS News Service |
|
2180242 07-Aug-2025 CET/CEST
Nachrichten zu Galenica AG
05.09.25 |
Galenica Aktie News: Galenica am Nachmittag mit Abschlägen (finanzen.ch) | |
05.09.25 |
Galenica Aktie News: Galenica wird am Mittag ausgebremst (finanzen.ch) | |
05.09.25 |
Galenica Aktie News: Galenica am Freitagvormittag freundlich (finanzen.ch) | |
03.09.25 |
SPI-Wert Galenica-Aktie: So viel Gewinn hätte ein Investment in Galenica von vor 3 Jahren abgeworfen (finanzen.ch) | |
27.08.25 |
SPI-Titel Galenica-Aktie: So viel Gewinn hätte ein Investment in Galenica von vor einem Jahr eingebracht (finanzen.ch) | |
13.08.25 |
SPI-Wert Galenica-Aktie: So viel Gewinn hätte ein Investment in Galenica von vor 5 Jahren abgeworfen (finanzen.ch) | |
07.08.25 |
Galenica-Aktie etwas tiefer: Galenica setzt sich nach Halbjahr höheres Gewinnziel (AWP) | |
07.08.25 |
Galenica wächst erfreulich und erhöht EBIT-Ausblick (EQS Group) |